Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC By Ogkologos - May 7, 2026 273 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source RELATED ARTICLESMORE FROM AUTHOR Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer MOST POPULAR Targeted prostate cancer screening: Are we there yet? October 20, 2021 Our 10 top tips to help you talk about cancer April 24, 2023 Reflections on Progress and Partnership at ASCO 2026 June 16, 2026 Online Dating During COVID-19 and Cancer: What to Know February 11, 2021 Load more HOT NEWS Kids Facing Difficult Medical Diagnoses Take Train To The ‘North Pole’... Starving cancer into submission Brentuximab May Mean Less Radiation for Children, Teens with Hodgkin Lymphoma French Senate Committee Backs ESMO Call to Revise EU Regulation to...
